We are live on
!
Find out more
DM
Deerfield Management Portfolio holdings
AUM
$8.48B
1-Year Est. Return
99.04%
This Fund
S&P 500
This Quarter
Est. Return
-0.6%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$2.74B
AUM Growth
+$257M
(+10%)
Cap. Flow
-$141M
Cap. Flow
% of AUM
-5.14%
Top 10 Holdings %
Top 10 Hldgs %
33.17%
Holding
165
New
42
Increased
42
Reduced
15
Closed
34
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ADVM
Adverum Biotechnologies
ADVM
|
+$60.9M |
| 2 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$57M |
| 3 |
MNK
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
|
+$40M |
| 4 |
WBA
Walgreens Boots Alliance
WBA
|
+$31.6M |
| 5 |
Globus Medical
GMED
|
+$26.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ITMN
INTERMUNE INC
ITMN
|
+$102M |
| 2 |
KERX
Keryx Biopharmaceuticals Inc
KERX
|
+$40.6M |
| 3 |
ZLTQ
ZELTIQ Aesthetics, Inc.
ZLTQ
|
+$23.8M |
| 4 |
AMAG
AMAG Pharmaceuticals
AMAG
|
+$20.7M |
| 5 |
HCA Healthcare
HCA
|
+$20.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 46.9% |
| 2 | Financials | 2.94% |
| 3 | Technology | 0.55% |
| 4 | Industrials | 0.34% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
AET
51
DELISTED
Aetna Inc
AET
| $13.7M | 0.5% |
169,194
+344
| +0.2% | +$28K |
|
52
Medtronic
MDT
$106B
| $12.7M | 0.46% |
204,800
+150,000
| +274% | +$9.54M |
|
53
Trupanion
TRUP
$1.16B
| $12.4M | 0.45% |
+1,455,377
| New | +$13.5M |
|
|
ICPT
54
CALL
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| $11.8M | 0.43% |
+50,000
| New | +$12.7M |
|
55
Inogen
INGN
$178M
| $11.4M | 0.42% |
552,337
+25,000
| +5% | +$508K |
|
|
CMRX
56
DELISTED
Chimerix, Inc.
CMRX
| $11.2M | 0.41% |
+406,100
| New | +$9.86M |
|
|
TRNX
57
DELISTED
TORNIER N V SHARES (NLD)
TRNX
| $11.2M | 0.41% |
469,007
-270,000
| -37% | -$6.03M |
|
|
NSTG
58
DELISTED
NanoString Technologies, Inc.
NSTG
| $11M | 0.4% |
1,003,974
+549,693
| +121% | +$6.8M |
|
|
ABMD
59
DELISTED
Abiomed Inc
ABMD
| $10.8M | 0.39% |
+435,934
| New | +$11M |
|
|
IMMU
60
DELISTED
Immunomedics Inc
IMMU
| $10.4M | 0.38% |
2,805,972
| – | – |
|
|
ALIM
61
DELISTED
Alimera Sciences
ALIM
| $10M | 0.37% |
123,459
+36,040
| +41% | +$3.08M |
|
|
KERX
62
PUT
DELISTED
Keryx Biopharmaceuticals Inc
KERX
| $9.63M | 0.35% |
+700,000
| New | +$10.7M |
|
63
AngioDynamics
ANGO
$558M
| $9.37M | 0.34% |
+682,740
| New | +$9.74M |
|
64
ProQR Therapeutics
PRQR
$240M
| $9.11M | 0.33% |
+530,000
| New | +$8.49M |
|
|
TTPH
65
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
| $8.98M | 0.33% |
22,510
+7,009
| +45% | +$1.88M |
|
|
WAGE
66
DELISTED
WageWorks, Inc.
WAGE
| $8.69M | 0.32% |
+190,770
| New | +$8.42M |
|
|
THOR
67
DELISTED
THORATEC CORPORATION
THOR
| $8.64M | 0.31% |
+323,136
| New | +$9.18M |
|
|
STRM
68
DELISTED
Streamline Health Solutions
STRM
| $8.44M | 0.31% |
121,517
+6,677
| +6% | +$468K |
|
|
LITS
69
Lite Strategy Inc
LITS
$33.6M
| $6.98M | 0.25% |
50,590
-6,029
| -11% | -$819K |
|
70
Alphatec Holdings
ATEC
$1.31B
| $6.77M | 0.25% |
331,895
| – | – |
|
|
WINT
71
DELISTED
Windtree Therapeutics Inc
WINT
| $6.73M | 0.25% |
261,407
| – | – |
|
|
CASM
72
DELISTED
CAS Medical Systems, Inc.
CASM
| $6.21M | 0.23% |
3,200,000
| – | – |
|
|
POZN
73
DELISTED
POZEN INC
POZN
| $5.99M | 0.22% |
816,254
+191,633
| +31% | +$1.54M |
|
|
PFNX
74
DELISTED
Pfenex Inc.
PFNX
| $5.99M | 0.22% |
+813,478
| New | +$5.21M |
|
|
BSTC
75
DELISTED
BioSpecifics Technologies Corp.
BSTC
| $5.96M | 0.22% |
168,883
| – | – |
|
Similar funds
FT
GRQ
AV
PCM
VA
QC
IC
NW
Deerfield Management's Q3 2014 Portfolio in Review
As of Q3 2014, Deerfield Management held 165 positions worth $2.74B, up 10% from $2.49B the previous quarter. Its ten largest holdings account for 33% of the portfolio.
Deerfield Management withdrew a net $141M in Q3 2014, closing 34 positions and reducing 15 holdings. Its most notable exit was INTERMUNE INC, an estimated $102M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 47% of assets, up from 42% a quarter earlier, followed by Financials and Technology.
Against the trend, Deerfield Management opened a new position in Adverum Biotechnologies worth $70M.
- Deerfield Management's largest Q3 2014 buy was Adverum Biotechnologies: 204,768 shares worth $70M.
- Deerfield Management added most to Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2014, an estimated $57M increase.
- Deerfield Management's biggest Q3 2014 reduction was Keryx Biopharmaceuticals Inc, cutting an estimated $40.6M.
- Deerfield Management fully exited INTERMUNE INC in Q3 2014, selling an estimated $102M.
- Deerfield Management's ten largest holdings make up 33% of its $2.74B portfolio in Q3 2014.
- Deerfield Management opened 42 new positions and closed 34 in Q3 2014.
- Deerfield Management's portfolio value rose 10% quarter-over-quarter to $2.74B.
Based on Deerfield Management's 13F filing for Q3 2014, filed 14 Nov 2014.